Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?
Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Shigeru
S
Kusumoto
Yasuhito
Y
Tanaka
Masashi
M
Mizokami
Ryuzo
R
Ueda
D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives*; D006509:Hepatitis B / Q000821:virology*; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D014775:Virus Activation / Q000187:drug effects*
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D006147:Guanine